Guotai Junan published a research report stating that considering the geopolitical risks of Wuxi Bio (02269.HK), it has lowered its adjusted net profit forecast for 2024 to 2026 to 4.919 billion, 5.623 billion, and 6.738 billion RMB, with earnings per share of 1.18, 1.35, and 1.62 RMB respectively. The target price has been lowered to 14.6 RMB, maintaining a 'shareholding' rating.

The bank stated that Wuxi Bio's new projects continue to grow, and its non-COVID-19 business development remains steady. The company maintains its full-year guidance unchanged. It will also continue to invest in overseas production capacity construction, with the expectation that by 2027, 40% of the capacity will be distributed in North America, Europe, and Singapore, supporting the globalized operation of the group.